{"organizations": [], "uuid": "b81d671fdb9573e7cb48d44c5b9ec42b17b7cf53", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sanofi-fda-to-conduct-priority-rev/brief-sanofi-fda-to-conduct-priority-review-of-cemiplimab-as-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSASO00040Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-30T13:05:00.000+03:00", "replies_count": 0, "uuid": "b81d671fdb9573e7cb48d44c5b9ec42b17b7cf53"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sanofi-fda-to-conduct-priority-rev/brief-sanofi-fda-to-conduct-priority-review-of-cemiplimab-as-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSASO00040Q", "ord_in_thread": 0, "title": "BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "fda to conduct priority review of cemiplimab", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - SANOFI SA:\n* REG-SANOFI: FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-30T13:05:00.000+03:00", "crawled": "2018-05-01T20:26:09.000+03:00", "highlightTitle": ""}